MONTREAL – Telus Health and McGill University have announced a new three-year, million dollar partnership to create a learning environment and conduct research on how best to use technology to improve health and healthcare delivery for Canadians.
“This partnership will contribute to our effectiveness in generating quantifiable results by allowing us to document patient outcomes from our health IT applications and cutting-edge collaborative services,” said Telus Health president Paul Lepage in a release. “It enables us to gain valuable knowledge and further insights on the impacts of ehealth initiatives from both the clinical and business perspectives on a national level.”
Through this partnership, the first study receiving funds will focus on understanding how remote health monitoring integrated with a patient health portal can be used to improve the management of complex medical therapy for patients with chronic cardiovascular disease, which affects over three million Canadians.
Widely used in chronic anticoagulant therapy for people living with cardiovascular disease, Warfarin requires close monitoring of patients, who currently must make regular visits to hospitals or clinics. This creates considerable inconvenience for patients, as well as being costly and inefficient.
The research project aims to help improve anticoagulation surveillance, while minimizing hospital visits and engaging the community with a patient-centred solution.
